

**Mayo Clinic Medical Edge**

**ER-CHOP**

1:00

| <b>Log</b>                  | <b>Audio</b>  |
|-----------------------------|---|
| <b>Intro with music</b>     | GIVING YOU THE EDGE ON HEALTHY LIVING, HERE'S MAYO CLINIC'S MEDICAL EDGE.   |
|                             | SOMETIMES MORE CAN BE BETTER. LIKE WHEN YOU'RE LOOKING FOR TREATMENTS OF DIFFUSE LARGE B-CELL LYMPHOMA.   |
| <b>Ivana Micallef, M.D.</b> | "WHICH IS ONE OF THE MOST COMMON TYPES OF NON-HODGKINS LYMPHOMA IN NORTH AMERICA AND FITS INTO THE CLASSIFICATION AS AN INTERMEDIATE GRADE OR AGGRESSIVE TYPE OF LYMPHOMA." |
|                             | DR. IVANA MICALLEF IS A MAYO CLINIC HEMATOLOGIST WHO LED A STUDY THAT ADDED AN ANTIBODY   |

|                     |  |
|---------------------|--|
|                     | <p>CALLED EPRATUZUMAB TO AN EXISTING TREATMENT REGIMEN OF RITUXIMAB AND CHOP CHEMOTHERAPY. THE ANTIBODY SPECIFICALLY TARGETS THE MALIGNANT B-CELLS. STUDY RESULTS SHOW A BETTER OVERALL SURVIVAL RATE, PLUS...</p> |
| <b>Dr. Micallef</b> | <p>“THE PATIENTS WHO HAD HIGH RISK DISEASE SEEMED TO BENEFIT THE MOST.”</p>  |
|                     | <p>WHILE THE RESULTS LOOK PROMISING, DR. MICALLEF SAYS MORE STUDY IS NEEDED.</p>   |
| <b>Dr. Micallef</b> | <p>“I WOULD URGE PATIENTS WHO ARE LOOKING FOR TREATMENT TO LOOK AT CLINICAL TRIALS BECAUSE I DO THINK CLINICAL TRIALS OFFER THE HOPE OF IMPROVING ABOVE THE STANDARD OF CARE.</p>                                  |
|                     | <p>FOR MORE INFORMATION, TALK TO YOUR DOCTOR OR VISIT <a href="http://MAYOCLINIC.ORG">MAYOCLINIC.ORG</a>. I'M VIVIEN WILLIAMS.</p>   |

